Ryzodeg Dosing
Start Ryzodeg at 16 units once daily, administered subcutaneously at the same time each day, and titrate by 2 units every 3-4 days based on fasting glucose targets. 1
Starting Dose
The recommended starting dose is 16 units once daily for patients transferring from basal insulin or initiating injectable therapy. This applies regardless of prior basal insulin dose, even for patients previously on 40-50 units of basal insulin daily 1.
Key Dosing Principles:
- Insulin-naive patients: Begin at 16 units once daily
- Patients on basal insulin: Switch directly to 16 units once daily, even if prior dose was higher
- Timing: Administer at the same time each day, with or without food
Titration Schedule
Adjust dose by 2 units every 3-4 days based on fasting plasma glucose measurements:
- Target fasting glucose: 80-130 mg/dL (4.4-7.2 mmol/L)
- Increase by 2 units if fasting glucose remains above target
- Decrease by 2-4 units if hypoglycemia occurs or fasting glucose drops below 70 mg/dL
Important Caveat for High-Dose Transfers:
Patients switching from 40-50 units of basal insulin to the 16-unit starting dose may experience a transient increase in fasting glucose during week 1 (mean increase ~1.1 mmol/L), but this normalizes by week 4 without clinical consequence 1. Do not panic and over-titrate during this brief period.
Maximum Dose
The maximum dose is 50 dose steps (50 units of insulin degludec/1.8 mg liraglutide) once daily. Each dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide in a fixed ratio.
Renal Impairment Adjustments
No dose adjustment is required for renal impairment based on the liraglutide component, as GLP-1 receptor agonists like liraglutide do not require dose modification across all stages of chronic kidney disease 2.
Critical Considerations:
- Initiate conservatively in patients with renal impairment to minimize hypoglycemia risk, particularly in those with eGFR <30 mL/min/1.73 m²
- Titrate more slowly (every 5-7 days instead of 3-4 days) in patients with moderate to severe renal impairment
- Monitor closely for hypoglycemia, as insulin clearance is reduced in renal dysfunction 3
- Avoid initiation during acute kidney injury, as insulin degludec clearance is significantly impaired in dynamic renal dysfunction, leading to prolonged hypoglycemia 4
Practical Algorithm for Renal Impairment:
- eGFR ≥60: Standard dosing (start 16 units, titrate every 3-4 days)
- eGFR 30-59: Start 10-12 units, titrate every 5-7 days
- eGFR 15-29: Start 10 units, titrate every 7 days with intensive glucose monitoring
- eGFR <15 or dialysis: Start 8-10 units, titrate every 7-10 days; consider alternative regimens if hypoglycemia becomes problematic
The lower starting doses in renal impairment align with general hospital insulin dosing principles, which recommend 0.1-0.25 U/kg for patients at high risk of hypoglycemia, including those with renal failure 3.
Clinical Advantages
Ryzodeg provides superior glycemic control compared to continued basal insulin up-titration (HbA1c reduction 5.86-6.91 mmol/mol greater) and comparable control to basal-bolus therapy, while offering weight loss instead of weight gain and lower hypoglycemia rates 1. The fixed-ratio combination allows adjustable liraglutide dosing alongside insulin, reducing GI intolerance compared to full-dose GLP-1 therapy 5.